ICIs have practically replaced docetaxel as the second-line treatment for advanced NSCLC, several ICIs demonstrated significantly longer OS than docetaxel, regarding to different PD-L1 expression level [22–29]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.